Trial · NCT00267085
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
NCT00267085, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2011-02-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease. Trials, record NCT00267085. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00267085
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
- NCT number
- NCT00267085
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Chronic Myeloid Leukemia, Minimal Residual Disease
- Interventions
- Synthetic Tumor-Specific Breakpoint Peptide Vaccine
- First posted
- 2005-12-20
- Last updated
- 2012-08-07
- Results first posted
- 2011-02-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response: One Log Decrease in BCR-ABL | 12 months | Molecular response defined as reduction by one log of the circulating peripheral blood for reverse transcription polymerase chain reaction (RT-PCR) transcripts of BCR-ABL (tumor-specific oncogenic fusion protein) after two consecutive measurements. RT-PCR performed at 3 month intervals. Response categorized as either 'No Decrease' or 'Decrease' if one log reduction in BCR-ABL detected. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response: One Log Decrease in BCR-ABL | 12 months | All 10 participants on study received treatment and were included in analysis. | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response: One Log Decrease in BCR-ABL | CML Vaccine | Decrease | 3 | Participants | |
| Response: One Log Decrease in BCR-ABL | CML Vaccine | No Decrease | 7 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CML Vaccine | 10 | |
| Overall Study | COMPLETED | CML Vaccine | 10 | |
| Overall Study | NOT COMPLETED | CML Vaccine | 0 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic Rhinitis | Respiratory, thoracic and mediastinal disorders | CML Vaccine | 1 | 10 | 1 |
| other | Bruising | Skin and subcutaneous tissue disorders | CML Vaccine | 2 | 10 | 2 |
| other | Dermatology/skin (other) | Skin and subcutaneous tissue disorders | CML Vaccine | 1 | 10 | 2 |
| other | Diarrhea | Gastrointestinal disorders | CML Vaccine | 4 | 10 | 4 |
| other | Erythema multiforme | Skin and subcutaneous tissue disorders | CML Vaccine | 1 | 10 | 1 |
| other | Fatigue | General disorders | CML Vaccine | 5 | 10 | 9 |
| other | Fever without neutropenia | General disorders | CML Vaccine | 1 | 10 | 1 |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | CML Vaccine | 10 | 10 | 31 |
| other | Nasal/paranasal reactions | Respiratory, thoracic and mediastinal disorders | CML Vaccine | 1 | 10 | 1 |
| other | Nausea | Gastrointestinal disorders | CML Vaccine | 2 | 10 | 2 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CML Vaccine | ||
| Total, other adverse events | CML Vaccine | 10 | 10 |
| Total, serious adverse events | CML Vaccine | 1 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00267085
GET https://conductscience.org/api/trials/v1/NCT00267085/registered